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Case presentation
A 52-year-old white man presented with transient ischemic attacks.
He recently had become short of breath and orthopneic, and had noted
ankle edema. Five years previously he had received a cadaveric renal
transplant because of renal failure from polycystic kidney disease. Both
his native kidneys had been removed prior to renal transplantation
because of recurrent urinary tract infection and pyelonephritis. He was
receiving azathioprine (150 mg daily) and prednisone (15 mg daily) for
immunosuppression, and nadolol (80 mg daily), nifedipine (20 mg 4
times daily), and hydrochlorothiazide (50 mg daily) for control of
hypertension. His renal function had been relatively stable during the
previous year with plasma creatinine values between 1.2 and 1.4 mg/dl,
and his blood pressure had been fairly well controlled when he was last
seen in the clinic 4 months previously.
On examination, his blood pressure had risen to 260/130 mm Hg. He
had grade-Ill funduscopic changes with prominent arteriolar narrowing,
areas of marked spasm, and hemorrhages and exudates in the retinae.
He did not have papilledema. He had basal rales in the lung fields
bilaterally. The renal allograft was palpable. A harsh systolic/diastolic
bruit was heard over the iliac region adjacent to the transplant.
Peripheral pulses were preserved. He had bilateral pedal edema. He
was admitted to the hospital, where his blood pressure was controlled
with intravenous labetalol and sodium nitroprusside. Furosemide (80
mg twice daily) was required to manage fluid retention and pulmonary
edema. A renal arteriogram showed a tight (> 90%) stenosis of the
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artery supplying the transplanted kidney approximately 2 cm distal to
the anastomosis. Immediately distal to the stenosis, the artery took a
90° turn and bifurcated into the two major renal branches. Because
radiologists considered this anatomic formation a high-risk setting for
angioplasty, the functional importance of this renal artery stenosis
(RAS) was investigated. The patient's blood pressure and cardiac
failure were controlled with oral nifedipine, 20 mg every 6 hours;
labetalol, 400mg every 6 hours; and furosemide, 80mg twice daily. One
week later, functional studies were undertaken 60 minutes after admin-
istration of a placebo on one day, or captopril (25 mg crushed and
suspended in water) on another. He had received no medications since
mid-day on the day previous to each study. Blood pressure was
measured with an automated recorder. Blood was drawn for plasma
renin activity (PRA) 60 minutes after drug administration. Thereafter,
he received doses of mTc]djethylenetriaminepefltaacetic acid
(DTPA) and ['3111-orthoiodohippurate (Hippuran). The glomerular fil-
tration rate (GFR) and renal plasma flow (RPF) were calculated from
the rates of plasma disappearance of these markers (Table 1) [1].
Captopril administration substantially reduced his blood pressure. The
PRA, already much elevated, rose fivefold further after captopril
administration. Captopnl reduced the GFR by 54%, yet increased the
RPF by 14%; thus the filtration fraction (FF) declined substantially. A
Hippuran renogram was normal after placebo administration but
showed a continuous renal cortical accumulation of Hippuran after the
patient received captopril. These findings indicated marked activation
of the renin-angiotensin-aldosterone (RAA) axis and angiotensin depen-
dency of GFR and the renogram, all of which are consistent with
functionally important renovascular hypertension. A renal artery an-
gioplasty was performed. The stenosed segment was successfully
dilated using a balloon-tip catheter. Three weeks later, his blood
pressure was 132/84mm Hg while he received nifedipine, 10mg 4 times
daily, and no diuretic. His serum creatinine concentration had fallen to
1.1 mg/dl. At followup 6 months later, his blood pressure and serum
creatinine remained at this level while he received this maintenance
dose of nifedipine.
Discussion
Da. CHRISTOPHER S. WILCOX (Associate Chief, Division of
Nephrology, Hypertension and Transplantation, andProfessor
of Medicine and Pharmacology; University of Florida; and
Chief, Nephrology and Hypertension Section, Department of
Veterans Affairs Medical Center, Gainesville, Florida): This
review will consider the physiologic basis for, and clinical
experience with, tests for renovascular hypertension based on
angiotensin-converting-enzyme (ACE)-inhibitor-induced changes
in blood pressure, PRA, renal vein renins, renal hemodynam-
ics, and renal scans. I will use results of studies in animal
models as a basis to review the responses to ACE inhibition in
human renovascular hypertension.
Renovascular hypertension in humans has a complex patho-
physiology. A reduction in renal perfusion pressure, often
accompanied by a reduction in blood flow to one or both
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Table 1. Effects of captopril on blood pressure, plasma renin activity,
and renal hemodynamics
After placebo After captopril
BP (mm Hg)a 180/110 104/72
PRA (ng Ang 1 mr' h') 23 128
GFR from [mTc]DTPA plasma
disappearance (ml min)
39 18
RPF from [1251]-Hippuran plasma
disappearance (m1 min)
292 334
FF(%) 13 5
a BP, blood pressure; PRA, plasma renin activity; GFR, glomerular
filtration rate; RPF, renal plasma flow; FF, filtration fraction.
kidneys, can be superimposed on other hypertensive factors
such as a hereditary predisposition to essential hypertension,
excessive salt intake, renal insufficiency, or loss of functioning
renal mass due to the effects of the upstream stenosis or the
prolonged effects of hypertension on the unprotected kidney.
Such heterogeneity in the underlying pathophysiology makes it
unlikely that any single diagnostic test based on interruption of
the renin-angiotensin-aldosterone system can universally dis-
criminate between renovascular and essential hypertension.
Most animal models of renovascular hypertension utilize a
renal artery clip or clamp to reduce the renal perfusion pressure
[2—4]. A single renal artery clip, with the other kidney remaining
in place (2 kidney, one clip, or 2K, 1C hypertension) is a model
of unilateral renal artery stenosis. A single renal artery clip with
the contralateral kidney removed (1K, lC hypertension) is a
model of transplant RAS or stenosis of a dominant kidney.
Bilateral RAS can have features of either model. The patho-
physiology of the 2K, lC model evolves through early, interme-
diate, and late phases [5]. Within hours of clipping, the blood
pressure, PRA, and plasma angiotensin II (All) levels rise. Rats
either show a negative sodium balance [6] or a transient positive
balance over one week followed by sodium loss [7]. However,
there is a sustained reduction in sodium excretion by the
clipped kidney and a maintained or increased excretion by the
contralateral kidney, despite similar levels of GFR and RPF [8].
The rise in blood pressure is largely independent of salt intake
[2]. After 2 to 4 weeks, hypertension enters an intermediate
phase characterized by a return of PRA and All levels towards
normal [9—111, although the PRA and All levels have remained
elevated in some studies [12—14]. In the chronic phase, 3—6
months after clipping, rats can develop a negative sodium
balance accompanied by a further increase in All and PRA with
the development of malignant hypertension [2], but in most the
PRA is within the normal range [2, 9]. Normal levels of PRA
and All are inappropriately high, however, when viewed in the
context of a sustained increase in blood pressure and reduced
GFR. Moreover, during the intermediate phase of 2K,1C hy-
pertension, renin secretion from the post-clip kidney can be
excessive and can be offset by inhibition of secretion by the
contralateral kidney; together these changes can maintain a
near-normal peripheral PRA [15]. In the conscious dog, the
early phase of elevated PRA and All levels lasts only for a few
days [3, 16, 17] unless the animals develop malignant hyperten-
sion and a precipitous reduction in renal blood flow [3].
The PRA values in 1K, lC rat models are usually normal [18]
but can be depressed [19]. Again, however, these values are
inappropriately high for the state of expanded total exchange-
able sodium [20], expanded plasma volume [21], and progres-
sive positive sodium balance [6]. The RAA axis of 2K,lC and
lK,1C rats remains responsive to changes in salt intake and
extracellular fluid volume during the development and mainte-
nance of renovascular hypertension [17, 22—24].
The animal studies of renovascular hypertension that I have
reviewed have led to the following predictions for the use of
PRA or All measurements in diagnosing human renovascular
hypertension: (1) Circulating PRA and All levels can be ele-
vated, especially early after the onset of renovascular hyper-
tension or during the malignant phase. However, normal values
also can be anticipated, especially in the chronic phase or
during high levels of dietary salt ingestion. (2) Renal-vein renin
estimation should be superior to peripheral PRA in the diagno-
sis of renovascular hypertension since the former can assess the
stimulation of renin secretion from the post-stenotic kidney and
the inhibition of renin secretion from the contralateral kidney.
The peripheral PRA is usually elevated in patients with
renovascular hypertension. However, even under ideal testing
conditions of controlled sodium intake in untreated subjects,
approximately 20% of patients with renovascular hypertension
have a normal PRA, whereas approximately 16% of patients
with essential hypertension have an elevated PRA [25—27].
Angiotensin I [1] and All [28] often are elevated in renovascular
hypertension, but this is not a consistent finding because of the
offsetting effects of secretion of renin by the post-stenotic
kidney and clearance of angiotensin by the contralateral kidney
[28]. Plasma levels of inactive renin also may be increased in
human renovascular hypertension, but the changes are gener-
ally less pronounced than for active renin [28].
The early studies of renal-vein renin testing reported a strong
correlation between positive findings of renin secretion by the
stenotic kidney with contralateral suppression of renin secre-
tion and a subsequent antihypertensive response following
correction of RAS [25, 29]. Subsequent studies, however, noted
that patients with RAS could be improved or cured by renal
revascularization or angioplasty without lateralizing renin val-
ues [28, 30—35].
Thus, tests based on static measures of peripheral or renal
venous PRA are inadequate for definitively diagnosing renovas-
cular hypertension. The introduction of the unselective All
antagonist, 1-sarcosine-8-alanine angiotensin II (saralasin), did
little to sharpen diagnostic criteria because of the effects of
varying agonist-like activity [36]. Efforts at improving diagnosis
of renovascular hypertension in the last decade have centered
on dynamic changes during ACE inhibition. These efforts will
form the basis for this Forum.
Antihypertensive response to ACE inhibitors
During the early phase (0 to 4 weeks) of 2K, 1C hypertension
in the rat or dog, administration of ACE inhibitors or saralasin
reduces the blood pressure abruptly [9, 10, 18, 37—45]. The
antihypertensive response is proportional to the PRA [39] or
plasma All concentration [9], is dose-dependent [14], and
appears to depend on All type-i receptors because it can be
mimicked by the selective All type-I receptor antagonist,
losartan [14]. During the intermediate phase (1 to 3 months) of
2K, IC hypertension in the rat, the antihypertensive response to
blockade of the RAA system is more variable and appears to be
Nephrology Forum: ACE inhibition in diagnosing renovascular hypertension 1381
Table 2. Post-ACE inhibition PRA values as a test for renovascular disease: Summary of studies reporting on 100 patients or more
Number
Source
with/without
RVH or RAS RVH or RASH
Sensitivity
(%)
Specificity
(%)
Muller et al [26Jb 40/112 RAS 100 95
Derkx et al [63] 89/90 RVH 84 93
Gosse et al [64] 11/106 (RAS) 73 85
Gosse et al [64]C 8/103 (RVH)C 100 84
Frederickson et al [27] 29/7 1 RAS 100 80
Postma [65]d 24/76 RAS 34—63 72—97
a RVH, renovascular hypertension; RAS, renal artery stenosis.
b Bracketed numbers refer to references.
C Three of the 11 patients with RAS had negative tests; all these patients failed to improve after angioplasty or surgery. The test was positive
in each of the remaining 8 patients with RAS.
ci These authors considered several criteria to evaluate the test. The results for sensitivity varied between 34% and 63% and for specificity
between 72% and 97%.
dependent on the PRA [39]. Saralasin infusion produces a
modest fall in blood pressure in the short term [38, 40]; one
study, however, reported that an infusion of saralasin or an
ACE inhibitor over 12 hours strikingly reduced blood pressure
to the normal range [46]. Likewise, oral captopril administered
over 5 to 7 days can normalize the blood pressure [18]. During
the chronic phase (3 to 6 months) of 2K,lC hypertension in the
rat, saralasin no longer produces a detectable antihypertensive
response, even when infused over 10 to 12 hours; captopril,
however, reduces blood pressure promptly, but only to a
modest degree [10, 12]. In a study of anesthetized chronic
2K,lC rats, we detected no significant reductions in blood
pressure with graded doses of captopril or with another ACE
inhibitor, benazaprilat; losartan, infused over 90 minutes, re-
duced blood pressure only modestly (15 mm Hg) [14].
The administration of angiotensin antagonists or ACE inhib-
itors to an acute (early) 1K, 1C model in the dog or rat delays the
onset of hypertension but does not prevent it [16, 18, 47—50]. In
the intermediate phase, these drugs do not affect the blood
pressure unless the animals have been salt-depleted, in which
case a clear-cut depressor response is seen [51]. Removal of the
renal artery clip during the early or intermediate phases of
2K,IC or IK,lC hypertension usually reduces the blood pres-
sure promptly to normal values [10, 12, 38, 52—54].
These animal studies predict that in patients with renovascu-
lar hypertension: (I) The immediate fall in blood pressure after
ACE inhibition will depend on the prevailing PRA or All levels.
(2) The antihypertensive response can be somewhat greater
during prolonged ACE inhibition therapy, but the blood pres-
sure is unlikely to return to normal.
The antihypertensive response to the first oral dose of an
ACE inhibitor in humans is directly proportional to the log of
the pretreatment PRA [55]. Interestingly, 3 prospective studies
have shown that the blood pressure of hypertensive subjects
with RAS during prolonged monotherapy with an ACE inhibitor
correlates with the blood pressure after reconstructive surgery
[56, 57], nephrectomy [56, 57] or percutaneous transluminal
renal angioplasty (PTRA) [58]. The overall correlation in the 3
trials between systolic or diastolic blood pressure during ACE
inhibition monotherapy before and after intervention is 0.64. A
systolic blood pressure below 160 mm Hg during ACE inhibitor
therapy predicted a successful antihypertensive response to
PTRA with a sensitivity of 89% and a specificity of 58% [58]. A
stepwise multiple regression analysis performed using these
data in conjunction with measurements of PRA revealed that
PRA, renal-vein renin levels, and blood pressure during ACE
inhibition monotherapy independently predicted the postoper-
ative blood pressure level [57]. This observation suggests that
some of the antihypertensive response to prolonged ACE
inhibition therapy in patients with renovascular hypertension is
independent of PRA or renal renin secretion. Whether these
effects of ACE inhibition in predicting post-intervention blood
pressure are specific for ACE inhibitors, or merely demonstrate
the presence of readily reversible hypertension, remains to be
established. The modest correlation coefficient (r = 0.64) sug-
gests that the blood pressure response to ACE inhibition
monotherapy is not sufficiently accurate to dependably predict
reversible renovascular hypertension. Other factors besides
excessive All generation apparently contribute to hypertension
in human renovascular disease.
Response of PRA to ACE inhibitors
Infusion of captopril into canine kidney decreases All levels
in renal lymph and increases the secretion of active renin into
the blood. In acute studies, an increase in the secretion of active
renin is matched by a reciprocal reduction in secretion of
inactive renin; total renin secretion is unchanged. This suggests
that short-term administration of captopril activates renin
within the kidney [59].
The administration of a dose of enalaprilat, which does not
alter PRA in normal dogs, increases PRA more than fourfold in
dogs with renal artery stenosis [60, 61]. Graded doses of
captopril given to conscious dogs markedly raise PRA only in
animals with a renal artery stenosis; this effect was not accom-
panied by changes in blood pressure [62]. The mechanism of the
exaggerated rise in PRA after ACE inhibition in renovascular
hypertension has not been elucidated by these studies but has
been dissociated from the fall in blood pressure [62]. These
results predict that in patients with renovascular hypertension
the diagnostic accuracy of a PRA value or of renal-vein renin
determinations will be enhanced by the administration of an
ACE inhibitor.
Muller et al analyzed the PRA values of a large group of
patients with hypertension before and one hour after oral
captopril administration [26]. The post-captopril PRA was a
more accurate predictor of renovascular hypertension than
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were the basal levels. Table 2 summarizes ACE inhibitor-
stimulated PRA values in 5 studies, each of which reported on
100 or more patients. The study by Muller et al was retrospec-
tive and therefore might have overestimated diagnostic accu-
racy [26]. Three of the five studies show a high sensitivity, 84%
to 100%. Gosse and coworkers reported a more limited sensi-
tivity of 73%, but 3 of their 11 patients with RAS failed to
respond to angioplasty or surgery; these were the 3 with
negative test results [64]. Exclusion of these 3 patients yields a
sensitivity of 100%. Using digital subtraction angiography or
arteriography, Postma and colleagues defined RAS as a 50% or
greater stenosis [651. Many of their subjects probably did not
have renovascular hypertension, given that hypertension from
renal artery stenosis is uncommon when the degree of RAS is
less than 75%. The inclusion of many patients with functionally
unimportant RAS could readily account for the low sensitivity
reported in this discordant study. We found that ACE inhibition
improved the discrimination of PRA for renovascular hyperten-
sion by a factor of approximately twofold [27].
The mechanism of the selective augmentation in PRA after
ACE inhibition in patients with renovascular hypertension has
not been established. It is not due to a greater fall in blood
pressure, as little correlation exists between changes in blood
pressure and PRA [27]. Moreover, an equivalent reduction in
blood pressure produced by clonidine does not raise the PRA
[11. The increase in PRA is due to increased secretion of renin
by the post-stenotic kidney; the renal-vein renin values at the
stenotic, compared with the contralateral, kidney increase
sharply after ACE inhibition, and the veno-arterial gradient for
renin across the contralateral kidney may decline further [66—
69]. Indeed, several studies have reported that administration of
an ACE inhibitor improves the diagnostic accuracy of renal-
vein renin sampling [66—69]. This observation was not con-
firmed, however, in one large study reported recently [70].
Two reasons probably explain why ACE inhibitors promote
an exaggerated release of renin from post-stenotic kidneys.
First, renal artery stenosis [71], and a reduction in renal
perfusion pressure [72], elicit a major release of renin and All
within the affected kidney, as reflected in measurements in
renal lymph. But intrarenal All strongly inhibits renin secretion
[59]. Therefore, ACE inhibitors might unmask the full stimulus
for renin secretion caused by the reduced perfusion pressure in
the post-stenotic kidney, a stimulus that had been blunted by
the inhibitory effects of intense local intrarenal All generation.
Second, ACE inhibitors reduce GFR, urine flow, and sodium
excretion selectively in post-stenotic kidneys but lead to no
change or an increase in these parameters in contralateral or
normal kidneys. The reduction in the filtered and excreted loads
of sodium in post-stenotic kidneys suggests that sodium chlo-
ride delivery to the macula densa is sharply reduced. A reduc-
tion in sodium chloride delivery could strongly stimulate renin
secretion and thus allow one to discriminate between function-
ally stenosed kidneys, in which GFR falls, and normal kidneys,
in which GFR can rise [73]. However, renin secretion after
ACE inhibitor administration has not been correlated with renal
hemodynamics in animal models or in human subjects with
renovascular hypertension.
Thus, in properly selected patients (see later), an elevated
PRA after ACE inhibitor administration has a high sensitivity
but a limited specificity for the diagnosis of renovascular
hypertension. The mechanism of this selective response in
patients with renovascular hypertension is independent of
changes in blood pressure and entails increased renin secretion
by the stenotic kidney by an as yet undefined mechanism.
Whether ACE inhibitors enhance the ability of renal-vein renin
sampling to detect functionally stenotic kidneys remains con-
troversial.
ACE-inhibitor-induced changes in renal hemodynamics
or the reno gram
During the intermediate phase of 2K, 1C hypertension, infu-
sion of an ACE inhibitor [37, 43] or saralasin [441 causes
strikingly divergent effects on the function of the clipped and
contralateral kidneys (Fig. 1). Despite a sharp fall in blood
pressure, the contralateral kidney experiences an increase in
RPF, GFR, urine flow, and sodium excretion. In contrast,
GFR, urine flow, and sodium excretion decline sharply in the
clipped kidney, but RPF is maintained. Some of the changes in
the clipped kidney might be secondary to a fall in renal
perfusion pressure below the autoregulatory range; similar
changes can be elicited by reducing the renal perfusion pressure
with an aortic clamp [44]. The fall in the GFR in the post-
stenotic kidney in response to administration of ACE inhibitors
or All antagonists probably entails a reduction in post-glomer-
ular vasoconstriction [16, 74—77]. However, it is technically not
possible to obtain reliable data using micropuncture in post-
stenotic kidneys after ACE inhibition. Therefore the details of
the mechanism of the fall in GFR remain speculative.
One study concluded that the renal hemodynamic response to
ACE inhibition in 1K,1C hypertension depends on the degree of
activation of the RAA system [77]. Administration of an ACE
inhibitor did not affect blood pressure, renal hemodynamics, or
sodium excretion in rats maintained on a normal salt intake for
3 to 4 weeks after clipping [77]. In contrast, the administration
of an ACE inhibitor to salt-depleted rats with IK,1C hyperten-
sion sharply reduced blood pressure, sodium and fluid excre-
tion, and GFR without significantly changing RPF [77]. In a
second study, however, an ACE inhibitor consistently reduced
GFR and did not alter RPF in 1K,lC rats maintained on a
normal salt intake. These responses were not altered by pre-
treatment with a loop or thiazide diuretic [78].
The single-kidney GFR and RPF can be estimated non-
invasively in animal or clinical studies using a combination of
plasma disappearance of a radioactive marker and scanning
techniques [79]. These estimates depend on the injection of
known quantities of suitable markers such as DTPA or Hip-
puran. Plasma is sampled thereafter to estimate the rate of
plasma clearance. It is assumed that DTPA is cleared via renal
filtration and Hippuran via renal filtration and secretion. Calcu-
lation of plasma clearance for the latter marker thus provides an
estimate of renal plasma flow. The contribution of each kidney
to total clearance of the marker is obtained by sampling counts
over the individual kidneys during the 2 to 3 minutes after its
administration while the marker is accumulating within the
renal parenchyma. These techniques have disclosed that in rats
with intermediate-phase 2K,1C hypertension, ACE inhibitors
reduce the GFR and FF of clipped, but not contralateral,
kidneys; these effects are augmented by prior furosemide
administration to stimulate the RAA system [80, 81]. Adminis-
tration of an ACE inhibitor also reduces uptake and clearance
* Fig. 1. Response to ACE inhibition in
renovascular hypertension in the rat. Mean
SEM values for mean arterial pressure,
glomerular filtration rate, urine flow rate, and
sodium excretion before and during
administration of teprotide to anesthetized
rats. Values are shown for the clipped (solid
triangles), and contralateral (solid circles)
kidneys of a 2K,1C rat model 2—4 weeks after
clipping and for a single kidney of normal rats
(open circles). Effects of teprotide: , P <
0.05; **, P < 0.01. (From Ref. 44 with
After permission.)
by the post-stenotic kidney of other markers that are filtered
and/or secreted by the kidney, including glucoheptanate, diami-
nosuccinic acid, aminated dextran, and lysozyme [811. Studies
in the conscious 2K,lC Goldblatt hypertensive dog also show
that ACE inhibition reduces GFR, urine flow [82—85], and the
rate of renal cortical elimination of markers in the post-stenotic
kidney [60, 61, 82—86]. These effects of ACE inhibition could
not be mimicked by equally antihypertensive doses of sodium
nitroprusside [83].
In an informative study in conscious dogs with a unilateral
RAS, Jonker et al found that shortly after ACE inhibitor
administration, a remarkable disparity emerged between the
strikingly reduced values of blood flow to the clipped kidney
when calculated from Hippuran clearance into the urine and the
increased values obtained via direct measurements from an
electromagnetic blood flow meter [82] (Fig. 2). Mannitol infu-
sion abolished the discrepancy between Hippuran clearance
and electromagnetic blood flow recording [82], but the ACE-
inhibitor-induced reduction in GFR in the clipped kidney per-
sisted during mannitol infusion. This experiment suggests that
after administration of an ACE inhibitor, the renal blood flow of
the clipped kidney is increased and thereby increases PAH
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delivery to the proximal tubule secretory sites. However, the
sharp reductions in GFR and urine flow rate greatly increase the
transit time from the proximal tubule to the renal pelvis and
thereby effectively trap Hippuran in the proximal tubular lu-
men. Mannitol infusion, which prevents the prolonged transit
time from the proximal tubule to the renal pelvis, prevents the
abnormal renal cortical retention of Hippuran. This hypothesis
predicts that the reduction in renal clearance of Hippuran into
the urine of a post-stenotic kidney following ACE inhibition
should be transient. A new steady state should be achieved
when Hippuran excretion becomes equivalent to Hippuran
secretion from the blood into the tubular fluid, providing that
the tubular fluid Hippuran concentration does not rise suffi-
ciently to become rate limiting for secretion by the tubule cells.
Jonker et al indeed did note a return of renal Hippuran
clearance in the clipped kidney towards baseline by 40 to 60
minutes alter ACE inhibition, but they did not follow the time
course further to determine whether complete normalization
occurred [82]. This study shows that estimates of renal plasma
flow using classical methods based on the renal clearance of
Hippuran into the urine can lead to an erroneous conclusion,
that is, that an ACE inhibitor has reduced the renal plasma flow
in a clippped or post-stenotic kidney, especially if the measure-
ments are made soon after administration of the agent. In
contrast, estimates of renal plasma flow from plasma Hippuran
disappearance and initial uptake by the kidney, as in the patient
under discussion (Table 1), should provide a more faithful
estimate of the true value of renal plasma flow. This discrep-
ancy might explain why some studies that have utilized renal
clearance methods with urine collection in 2K,1C models have
concluded that ACE inhibitors or angiotensin antagonists re-
duce the renal plasma flow of clipped kidneys [44, 45, 82], yet
others that have used measurements of plasma Hippuran dis-
appearance and renal uptake have concluded that ACE inhibi-
tors increase the renal plasma flow of clipped kidneys (Table 1)
[60, 61, 85]. This explanation also could account for the finding
that ACE inhibitors cause cortical retention and delayed elim-
ination from the clipped kidney not only of Hippuran but also of
a number of markers that are either filtered or secreted into the
tubular fluid [81]. Prior extracellular fluid volume depletion
should further delay the cortical elimination of markers in
clipped kidneys by ACE inhibitor administration because the
GFR becomes more dependent on All in salt-depleted animals
[75] and extracellular fluid volume depletion increases proximal
tubule fluid reabsorption, thereby further prolonging transit
time down the nephron [87].
The reports of the effect of ACE inhibitors on the renal
hemoctynamics of 1K, 1 C models are more variable. Adminis-
tration of an ACE inhibitor to a salt-depleted dog reduced the
GFR in a solitary stenosed renal transplant [88], but no signif-
icant effect was seen in a IK,IC dog model [84]. In the rat,
however, ACE inhibition strikingly reduced the GFR of a
solitary clipped kidney despite only a modest reduction in blood
pressure [78].
These findings lead to the following predictions for use of
nuclear medicine scans for diagnosing angiotensin-dependent
renovascular hypertension in humans: (1) An ACE-inhibitor-
induced reduction in GFR and delayed cortical elimination of
markers should be useful diagnostic indices for renovascular
hypertension. (2) The sensitivity of these tests is increased by
prior salt depletion with diuretics, especially in the presence of
stenosis of a transplanted or single surviving kidney. (3) De-
layed cortical elimination of a tracer alter administration of an
ACE inhibitor is a function of the changes in renal hemodynam-
ics and not of the nature of the tracer, providing the tracer is
eliminated by filtration and/or tubular secretion.
The diagnostic accuracy of renal scanning after ACE inhibi-
tion has been reviewed recently [89—92]. These reviews contain
details of the tests used and their interpretation. Diagnostic
criteria for renovascular hypertension based on either a selec-
tive reduction in GFR in the post-stenotic kidney or a delay in
cortical elimination of isotope alter ACE inhibition yield sensi-
tivities of 44% to 96% and specificities of 42% to 100%. One
recent study reported that a delay in renal cortical Hippuran
elimination after ACE inhibition in furosemide-treated patients
with RAS predicted an antihypertensive response to percuta-
neous transluminal renal angioplasty with a sensitivity of 96%
and a specificity of 95% [93]. Almost equally good results have
been reported by some investigators using DTPA as the marker
[94—97].
The ACE inhibitor-induced decline in GFR in the post-
stenotic kidney appears not to be the consequence of a mild to
moderate fall in blood pressure because such a decline is not
reproduced by an equivalently antihypertensive dose of cloni-
dine [1] or sodium nitroprusside [98]. A particularly abrupt
reduction in blood pressure, however, can reduce the GFR of
post-stenotic kidneys [98].
A delay in the renal clearance of a tracer alter ACE inhibition
might be caused by a delay in pelvic emptying rather than by a
delay in nephron transit. This potential artifact should be
apparent by inspection of the individual renal tracer profiles.
Administration of furosemide 3 minutes after Hippuran in-
creases the sensitivity of the renogram for detecting renovas-
cular hypertension by washing out of the tracer from the pelvis
[93]. This maneuver allows whole-kidney counting to provide a
more accurate index of the activity-versus-time profile for the
tracer in the renal parenchyma.
We studied the mechanism of the ACE-inhibitor-induced
delay in Hippuran elimination in one patient with a normal right
renal artery but a 75% to 85% left renal artery stenosis. The
RPF was calculated from the plasma Hippuran disappearance
and the initial renal uptake of the tracer. Prior to ACE inhibi-
tion, the renogram was similar in the two kidneys, although the
RPF was reduced in the post-stenotic kidney (Fig. 3A). Capto-
pril administration prompted a continuous accumulation of
Hippuran in the post-stenotic kidney throughout the 30 minutes
of the scan despite an increase in the RPF (Fig. 3B). Adminis-
tration of furosemide (40 mg IV given with the Hippuran) did
not prevent the early renal cortical accumulation of Hippuran
but led to a partial correction after the first 15 minutes (Fig. 3C).
In contrast, an infusion of mannitol given after captopril (25 g of
mannitol in 250 ml of isotonic dextrose solution infused over 35
minutes starting 5 minutes before the administration of Hip-
puran) abolished the difference in the renograms between the
two kidneys (Fig. 3D). Neither furosemide nor mannitol
changed the calculated RPF. These data in a human subject
with hypertension indicate that an abnormal cortical retention
of Hippuran in the post-stenotic kidney following ACE inhibi-
tion is due to retention of the tracer in the proximal tubular
fluid. Furosemide, which should decrease tubular fluid transit
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Fig. 3. Hippuran renograms of patient with
unilateral renal artery stenosis. Individual
values for Hippuran renograms from a patient
with a 75% to 85% stenosis of the left renal
artery and an angiographically normal right
renal artery. Renograms were performed on
each occasion one hour after 50 mg of
captopril or placebo given orally. In A, a
placebo was given in place of captopril; B,
captopril alone was administered; C,
furosemide (40 mg IV) was given with the
Hippuran tracer; D, mannitol was infused for
5 mm before and throughout the period of the
Hippuran renogram. Values for ERPF were
calculated from the rate of plasma
disappearance and initial uptake by the two
kidneys. Interrupted line, right kidney;
continuous line, left kidney.
Fig. 4. Relationships between positive and
negative predictive values and prevalence of
renovascular hypertension in the test
population for three sets of sensitivity and
specificity values.
Test characteristics:
Sensitivity
(%)
75
95
95
Specificity
(%)
75
80
95
time only in the distal nephron downstream from its major site
of action in the loop of Henle, only partly reversed this effect.
But mannitol, which reduces the transit time throughout the
entire nephron, fully reversed it.
Conclusions
Static tests for the presence of renovascular hypertension
based on the measurement of basal values of components of the
renin-angiotensin system have only limited sensitivity and
specificity, that is, about 75% to 85%. The blood pressure
response during steady-state treatment with an ACE inhibitor
provides a rough measure of the blood pressure level likely to
be achieved after repair of renal artery stenosis. It is not yet
established whether this effect is specific for ACE inhibitors.
The diagnostic accuracy of a peripheral PRA value is increased
considerably after ACE inhibition. A simplified captopril chal-
lenge test performed under ideal protocol conditions can yield a
very high sensitivity (approximately 95%) but has a limited
specificity (80% to 90%). The mechanism of ACE-inhibitor-
induced hypersecretion of renin from the post-stenotic kidney
may entail a selective reduction in GFR of the affected kidney,
thereby curtailing macula densa sodium chloride delivery and
reabsorption or an escape from inhibition of renin secretion by
All formed locally within the kidney. Administration of an ACE
inhibitor reduces GFR, urine flow, and sodium excretion selec-
tively in the post-stenotic kidney. These reductions can be
detected by GFR markers or by a delay in the cortical elimina-
tion of markers that are filtered by the glomerulus or secreted
by the tubules. Under ideal protocol conditions, these ACE-
inhibitor-induced changes in GFR or renal scans can predict a
favorable antihypertensive response to percutaneous translumi-
nal renal angioplasty with sensitivities and specificities as high
as 95%.
Figure 4 details the relationships between the prevalence of
renovascular hypertension in the test population and the posi-
tive and negative predictive values of the tests. Even a test with
a truly outstanding sensitivity and specificity of 95% is inade-
quate for screening an unselected population of hypertensive
patients in whom the prevalence of renovascular hypertension
is less than 1%. At this level of prevalence, the positive
predictive value is less than 10%. Thus, if arteriograms were
performed in patients with a positive test result, only one
patient with renovascular hypertension would be detected for
each 10 arteriograms undertaken. The other 9 patients would be
subjected to unnecessary expense, inconvenience, and poten-
tially adverse effects from this procedure. The use of clinical
clues, however, can lead to the selection of a group of hyper-
tensive patients with a prevalence of renovascular disease of
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5% to 20% [91]. At this level of prevalence, tests with a
sensitivity as high as 95%, whether accompanied by a moderate
specificity (for example, 80%, as is typical of ACE-inhibitor-
induced increases in PRA) or by a very high specificity (for
example, 95%, as typified by the best results with ACE-
inhibitor renography), carry very high negative predictive val-
ues of greater than 95%. Therefore, a negative result with either
test can be used as an indication that further workup is
unnecessary. Some patients present with hypertension and a
RAS discovered coincidentally during angiography for investi-
gation of coronary or ilio-femoral vascular disease. Hyperten-
sion in the majority of patients with a stenosis of 75% or greater
generally is improved or cured by reversal of the stenosis.
Thus, this group has a very high prevalence (approximately
60% to 80%) of renovascular hypertension. At this prevalence,
tests having both a high sensitivity and a high specificity of 95%
carry very high positive and negative predictive values of
greater than 90%. Therefore, either a positive or a negative test
result is very informative in these patients and should be helpful
in predicting the outcome of a planned intervention to correct
the renal artery stenosis.
Further studies will be needed to assess the accuracy of ACE
inhibitor-induced changes in PRA and renography in popula-
tions with varying prevalences of renovascular hypertension.
However, results currently available indicate that tests based
on functional responses to ACE inhibition might be sufficiently
accurate to help clinicians screen selected groups of patients for
this important and curable form of hypertension.
The patient presented here exemplifies an unusually acute
form of renovascular hypertension that arose due to stenosis of
the artery supplying a previously normal kidney. The prior
native nephrectomies simplified the interpretation of the func-
tional changes in the transplanted kidney with a renal artery
stenosis. This man had marked angiotensin dependency of
blood pressure, PRA, GFR, and renal cortical Hippuran elimi-
nation, which was probably potentiated by the diuretic therapy
required to control fluid retention. The RPF was calculated
from plasma Hippuran disappearance without the need for renal
scanning, as the patient had only one remaining kidney. The
calculated RPF was increased after captopnl administration
despite a major reduction in blood pressure (Table 1) and
continuous cortical Hippuran accumulation shown on the reno-
gram. These changes were anticipated from studies of the
effects of ACE inhibition on animal models of early renovascu-
lar hypertension. Several studies have noted that marked and
reversible reductions in GFR occur after administration of ACE
inhibitors to patients with stenosis of a transplanted or solitary
kidney [99—101]. Early detection and reversal of functionally
important RAS, as in this patient, is important, because pro-
longed RAS might lead to irreversible atrophy of the stenosed
kidney and persistent hypertension despite technically success-
ful renal artery surgery or angioplasty.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): In the
interest of time, you did not elaborate on possible differences
among the various tracers used for renography. Could you
address briefly the characteristics of [mTcJ DTPA, [''l]
orthoiodohippurate, and [mTc] MAO3? Also, in your analysis
of the results of various studies on captopril renography, it was
not clear whether patients with abnormal renal function were
included. What are the results of captopril renography in
patients with ischemic renal disease?
DR. WILCOX: DTPA is a glomerular filtration rate marker;
Hippuran and MAO3 are transported by proximal tubule cells
into the tubular fluid [102]. DTPA and Hippuran are well-
studied markers for GFR and renal plasma flow, respectively.
MAO3 has been less intensively studied, but it appears to
combine the high levels of renal uptake characteristic of Hip-
puran with the superior imaging that is achieved with mTc.
Under protocol conditions, the sensitivity of either DTPA or
1-Jippuran in predicting a favorable blood pressure response to
angioplasty are similar and can exceed 90% [89—92].
One recent study of patients with impaired renal function
contrasted the Hippuran renogram after administration of an
ACE inhibitor in patients with renovascular hypertension com-
pared with patients with intrinsic renal disease [93]. Both
groups showed a continuous cortical accumulation of Hippuran
or a delay in the cortical elimination of Hippuran. When the test
was repeated without ACE inhibitor pretreatment, however,
this effect reversed somewhat in the patients with renovascular
hypertension, but not in those with intrinsic renal disease.
Erbsloh-Moller et al recommend this protocol in patients with
impaired renal function for detecting reversible renovascular
hypertension [93]. However, further studies are required, par-
ticularly those using DTPA, to determine whether renal insuf-
ficiency impairs the accuracy of ACE-inhibitor renography for
detection of renovascular hypertension as it does the accuracy
of the captopril-stimulated PRA test [26].
DR. MADIA5: Doesn't this run counter to the clinical experi-
ence in patients with parenchymal renal disease who are treated
with ACE inhibitors? The GFR in such patients commonly
drops initially, at least over the first few weeks, and then it
stabilizes.
DR. WILCOX: I agree. Currently, we do not undertake ACE
inhibitor-based screening tests in patients with creatinine clear-
ance values below 30 mI/mm. This is a serious limitation of
testing, because patients with impaired renal function are at
increased risk during arteriography. Therefore, in the absence
of well-characterized tests for these patients, one is left with a
dilemma: whether or not to perform a contrast renal arterio-
gram, which can further jeopardize their renal function. Our
solution is to use carbon dioxide angiography [103] or magnetic
resonance angiography (MRA) [104] in these patients, because
these techniques appear to carry less risk of nephrotoxicity.
However, these new approaches require systematic validation
before they can be recommended for routine use.
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook, Stony Brook, New
York): I was pleased that you chose to emphasize the economic
impact of various tests in the evaluation of the hypertensive
patient because considerations of cost-effectiveness are becom-
ing increasingly relevant to clinical decision-making. With this
in mind, I am interested in knowing this: for what fraction of
patients with a sufficiently high index of suspicion for renovas-
cular disease to qualify for tracer angiography do you end up
not ordering an aortogram? If the fraction is low, might it not be
more cost-effective to first undertake aortography?
DR. WILCOX: In our experience, the sensitivity of an ACE
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inhibitor-induced increase in PRA is as good as an ACE
inhibitor-induced change in the renogram. The cost of the PRA
study is substantially less. Therefore, we use the captopnl-
stimulated PRA as the screening test and reserve the ACE
inhibitor-induced changes in the renogram to evaluate patients
after aortography where doubt remains about the functional
significance of the lesion, or when the patient is at high risk for
intervention. As Figure 4 indicates, the negative predictive
value of a test with a high sensitivity exceeds 98%. This is
sufficiently reassuring for us to defer aortography in patients in
whom the level of clinical suspicion is moderate. I agree that
there are some patients who are judged to be very likely to have
renovascular hypertension. They would be studied by aortog-
raphy whatever the results of a screening test. Therefore, it is
not logical to apply screening tests to this selected group.
DR. COHEN: The flip side of that question is: why not first use
the potent antihypertensive agents we now have available to
treat patients, even those with a high index of suspicion for
renovascular disease, without further testing, and apply your
expensive diagnostic procedures only to those who are either
intolerant of, or do not comply with, the antihypertensive
therapy?
DR. WILCOX: That is a good question that can only be
addressed by a controlled clinical trial to compare PTRA with
optimal medical therapy. Dr. Davidson and I have initiated such
a trial recently. However, one problem with delaying PTRA or
reconstructive surgery is that atherosclerotic renal artery ste-
nosis frequently progresses. Therefore, a recommendation to
delay intervention carries the risk that it might no longer be
feasible if the renal artery becomes completely stenosed or
thrombosed. In our trial, the medically treated patients have
close surveillance for changes in renal function or size, and
optimal therapy for control of factors that can accelerate
progression of atherosclerosis, including hypertension, dyslip-
idemia, and smoking.
DR. COHEN: One final question. Do you vary your diagnostic
strategy by age? That is, for a given index of suspicion, do you
recommend anything different for the younger versus the older
patient?
DR. WILCOX: That is another interesting point. We have
recently retrospectively analyzed the antihypertensive re-
sponse to PTRA or surgery in the last 71 patients with a renal
artery stenosis of 75% or greater managed at our institution
(Barn YM, Wilcox CS, Davidson RA, Sendler S, unpublished
observation). Age was an important predictor of outcome. The
chances of cure of hypertension decreased sharply with increas-
ing age. This was true for the patient with fibromuscular
dysplasia or atherosclerotic disease. Therefore, we search
particularly diligently for RAS in young patients, and we have a
lower threshold for intervening with PTRA or surgery in them.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You mentioned
in your discussion that the rise in PRA after captopril adminis-
tration was due not only to an increase in renal secretion of
renin but to its activation. Could you expand on those studies?
DR. WILcox: We observed that within one hour of infusion of
captopril into the renal artery of salt-depleted dogs, the secre-
tion of active renin increased, and this rise was offset by a
reduction in the secretion of inactive renin; the total renin
secretion rate into the renal venous plasma was unchanged [591.
A similar reciprocal change in plasma active and inactive renin
after ACE inhibition has been found in some [105], but not all
[106], studies in humans. This change suggests that one acute
effect of ACE inhibition is the activation of preformed inactive
renin in the kidney. The details of the mechanism of this
activation process remain unclear.
DR. MADIAS: Is there any experience with the use of an
angiotensin H receptor antagonist, such as losartan, in the
diagnosis of renovascular hypertension with regard to changes
in PRA or renography? This agent might have advantages over
ACE inhibitors since it is devoid of effects on prostaglandins
and the kinin system.
DR. WILCOX: I am not aware of any specific information on
this point. We find that losartan and ACE inhibitors have
similar antihypertensive actions in early 2K, IC rat models, but
we have not yet compared their effects on PRA or renal
hemodynamics.
DR. RICHARD KOPELMAN (Acting Chief, General Medicine
Division, New England Medical Center): What effect, if any,
does the patient's salt intake have on the results of the captopril
challenge test?
DR. WILcox: We do not regulate salt intake for this test. In a
previous study, we contrasted the results of the captopril test in
a subgroup of patients who continued their diuretic therapy
with a group who had not received diuretics for the previous 2
weeks. Diuretic therapy reduced the specificity of the test from
86% to 70% but did not alter the sensitivity, which was 100% in
both groups [27]. Most investigators recommend that salt intake
not be assessed or altered prior to this test. Indeed, this is one
of its attractions, as the test can be performed in the outpatient
setting without the need for cumbersome manipulation of salt
intake. However, diuretic drugs should be withdrawn where
possible 2 weeks prior to testing.
DR. RONALD PERRONE (Division of Nephrology, New Eng-
land Medical Center): In preparation for renography, do you
treat patients with either short-acting calcium-channel blockers
or alpha blockers for a period of time prior to study?
DR. WILCOX: One study indicates that it is not necessary to
discontinue antihypertensive agents, except for ACE inhibitors,
prior to DTPA renography [94]. However, some antihyperten-
sive agents, notably beta blockers, can suppress renin secretion
sufficiently to lead to a false-negative result in the captopril
PRA test [26]. Our routine is to maintain patients who require
antihypertensive therapy on a calcium antagonist and/or an
alpha-beta blocking drug such as labetalol for 2 weeks prior to
captopril challenge or captopril renography. These drugs are
not taken on the day of study. This regimen appears to work
well, but it has not been formally evaluated. We consider that
patients who have an absolute requirement for a diuretic or an
ACE inhibitor should be excluded from functional testing.
DR. PERRONE: My question Was related to that point. You
also excluded patients with abnormal renal function, and I
suspect that approach would exclude a significant portion of
patients with bilateral atherosclerotic disease. How do you
implement these exclusion criteria in a practice setting?
DR. WILCOX: Interpretation of a DTPA renogram becomes
inaccurate at a single-kidney GFR below 15 mI/mm. However,
Hippuran ACE inhibitor renography might be helpful in diag-
nosing renovascular hypertension in patients with significant
impairment of renal function [93]. Interestingly, most studies
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find that patients with bilateral renal artery stenosis have an
equally impressive increase in PRA or change in the renogram
after captopril as those with unilateral RAS [27, 63]. Indeed, it
is often the increase in blood urea nitrogen or serum creatinine
concentration during ACE inhibitior therapy that first alerts
physicians to the presence of bilateral renal artery stenosis.
DR. HARRINGTON: My question is not directly related to your
discussion, but the issue of renal angiograms did come up.
What's the latest information on MRI renal angiography? Will
that technique afford a safer look at the renal vessels than
approaches over the last 30 years have offered?
DR. WILCOX: In one blinded study of 37 patients, two-
dimensional magnetic resonance angiography had a sensitivity
of 100% and a specificity of 94% for detecting a RAS of 50% or
greater [104]. All patients could be scanned successfully. Inter-
pretation of the scans requires several images [104]. Problems
can be encountered because turbulent blood flow can exagger-
ate the apparent stenosis, and imaging is not adequate to define
the intrarenal vessels. However, this technique is clearly safer
than arteriography because it requires no intravascular cathe-
terization, nor does it require administration of x-ray contrast
agents or exposure of the patient to radiation. It has substantial
potential, which has yet to be explored systematically.
DR. MADIAS: What about unilateral parenchymal renal dis-
ease? Is it commonly associated with a false-positive result on
captopril renography?
DR. WiLcox: Unilateral renal parenchymal disease and renal
artery stenosis are both associated with a decrease in the rate of
cortical elimination of Hippuran. However, one study has
indicated that a change in the rate of cortical elimination of
Hippuran after an ACE inhibitor is a specific indication of
renovascülar hypertension and might be used to dissociate this
from renal parenchymal disease [93].
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